case Mainland China English summary

Kangmei Pharmaceutical Special Representative Securities Litigation

投资者保护典型案例(一):全国首例证券纠纷特别代表人诉讼案——康美药业案

The first special representative securities litigation in China, resolving claims by more than 52,000 investors arising from Kangmei's large-scale financial fraud.

Brief English Introduction

Kangmei is the landmark test of the Securities Law’s special representative litigation mechanism and the opt-out style protection of dispersed public investors.

Use It For

Use this case for securities class-action design, director and controller accountability, gatekeeper liability, and mass-investor compensation.

Teaching Notes

Ask students how special representative litigation changes the settlement leverage of public investors compared with ordinary individual claims.